Goodwin’s Guidance on TalkMed Group Limited Privatization
A team at Hong Kong’s Private Equity group, led by Goodwin, recently advised TW Troy Limited (“TW Troy”) on its planned acquisition of all the shares in TalkMed Group Limited (“TalkMed”). TalkMed is a leading provider of medical oncology, stem cell transplant, and palliative care in Singapore and is publicly listed on the Mainboard of the Singapore Exchange Securities Trading Limited.
The acquisition will involve a scheme of arrangement under the Companies Act of Singapore and the Singapore Code on Take-overs and Mergers, with the goal of privatizing TalkMed. TW Troy, a special purpose vehicle created for this deal, is indirectly owned by Tamarind Health Limited, a company controlled by Templewater, an alternative asset manager. Tamarind Health is a pan-Asian oncology-focused group based in Singapore with various healthcare facilities across different countries in Asia.
As part of the transaction, 65 Equity Partners, a global investment firm based in Singapore and backed by Temasek, will invest in Tamarind Health through its Local Enterprise Fund, which aims to support regional champions in Singapore.
Templewater, founded in 2018, is an Asia-based asset manager offering private equity investments in the Asia Pacific region, as well as focusing on decarbonization and energy transition globally. The team also manages a real estate fund concentrating on investments in Australia and New Zealand. Their mission is to provide financial backing, operational expertise, and integrity to build successful businesses.
The Goodwin team, led by Edwin Chan, and including other experts in various fields, provided essential support throughout the deal. For more information on this investment, refer to the official press release.
